Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.002 AUD | -33.33% | -33.33% | -42.86% |
May. 16 | Avecho Biotechnology Doses First Patient in Phase III Anti-Insomnia Drug Trial | MT |
Mar. 25 | Avecho Biotechnology Begins Patient Recruitment for Phase Three Anti-Insomnia Drug Trial | MT |
Business Summary
Number of employees: 15
Sales per Business
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Production
100.0
%
| 1 | 100.0 % | 0 | 100.0 % | -58.07% |
Sales per region
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Switzerland
85.2
%
| 1 | 89.4 % | 0 | 85.2 % | -60.05% |
Australia
8.1
%
| 0 | 2.2 % | 0 | 8.1 % | +56.03% |
India
6.7
%
| 0 | 2.3 % | 0 | 6.7 % | +24.70% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Paul David Gavin
CEO | Chief Executive Officer | - | 01-12-31 |
Melanie Leydin
DFI | Director of Finance/CFO | 51 | 18-12-27 |
Roksan Libinaki
COO | Chief Operating Officer | - | 00-12-31 |
Ross Murdoch
BRD | Director/Board Member | - | 15-01-13 |
Corporate Officer/Principal | - | 06-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Ross Murdoch
BRD | Director/Board Member | - | 15-01-13 |
Director/Board Member | 60 | 20-01-12 | |
Gregory Collier
CHM | Chairman | - | 15-04-12 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 3,169,297,013 | 2,078,984,865 ( 65.60 %) | 0 | 65.60 % |
Company contact information
Avecho Biotechnology Ltd.
2A Westall Road Unit A8
3168, Clayton
+61 3 9002 5000
http://www.avecho.com.auSector
Sales per Business
Sales per region
1st Jan change | Capi. | |
---|---|---|
-42.86% | 4.31M | |
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |
- Stock Market
- Equities
- AVE Stock
- Company Avecho Biotechnology Limited